ArticleCancer discovery2015

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Paul K Paik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.